Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 149Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Non-Hodgkin 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 81Hodgkin Disease 81Small Cell Lung Carcinoma 79Leukemia, Myeloid, Acute 73Burkitt Lymphoma 69Lymphoma, Follicular 67Lymphoma, Mantle-Cell 65Lung Neoplasms 60Lymphoma, Large-Cell, Immunoblastic 54Leukemia, Lymphocytic, Chronic, B-Cell 47Recurrence 40Multiple Myeloma 39Lymphoma, B-Cell, Marginal Zone 36Neuroblastoma 33Congenital Abnormalities 29Carcinoma, Non-Small-Cell Lung 28Lymphoma, B-Cell 25Myelodysplastic Syndromes 24Lymphoma, Large-Cell, Anaplastic 23Lymphoma, Extranodal NK-T-Cell 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Brain Neoplasms 22Sarcoma 21Ovarian Neoplasms 21Lymphoma, T-Cell, Peripheral 20Central Nervous System Neoplasms 20

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Extensive Stage Lung Small Cell Cancer × Etoposide × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡